In the last three months, 20 analysts have published ratings on Sage Therapeutics SAGE, offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 13 | 1 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 1 |
| 3M Ago | 1 | 2 | 9 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.35, a high estimate of $28.00, and a low estimate of $8.00. This current average has decreased by 23.46% from the previous average price target of $25.28.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Sage Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anupam Rama | JP Morgan | Lowers | Overweight | $18.00 | $23.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $25.00 | $25.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $23.00 | $28.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $25.00 | $25.00 |
| Joel Beatty | Baird | Maintains | Neutral | $15.00 | $15.00 |
| David Hoang | Citigroup | Announces | Sell | $8.00 | - |
| Joel Beatty | Baird | Announces | Neutral | $15.00 | - |
| Anupam Rama | JP Morgan | Lowers | Overweight | $28.00 | $29.00 |
| Douglas Tsao | HC Wainwright & Co. | Lowers | Neutral | $25.00 | $28.00 |
| Salveen Richter | Goldman Sachs | Lowers | Neutral | $19.00 | $28.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $15.00 | $26.00 |
| Joon Lee | Truist Securities | Lowers | Hold | $18.00 | $22.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $18.00 | $20.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Hold | $17.00 | $21.00 |
| George Farmer | Scotiabank | Lowers | Sector Outperform | $19.00 | $34.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $17.00 | $25.00 |
| Ritu Baral | TD Cowen | Lowers | Buy | $16.00 | $30.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Neutral | $28.00 | $28.00 |
| Laura Chico | Wedbush | Maintains | Neutral | $24.00 | $24.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Underperform | $14.00 | $24.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sage Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Sage Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sage Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Sage Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Understanding the Numbers: Sage Therapeutics's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Sage Therapeutics showcased positive performance, achieving a revenue growth rate of 139.89% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1372.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sage Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -14.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sage Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -13.15%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
